Prostate Specific Membrane Antigen PET/CT Imaging in PSMA-Related Disease Patients

Launched by TIANJIN MEDICAL UNIVERSITY · Nov 14, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a special type of imaging called PSMA PET/CT scan to see how helpful it is in finding prostate cancer and other related diseases. The goal is to see if this imaging technique can effectively identify both new and existing tumors in patients who have or are suspected to have prostate cancer or other conditions related to PSMA. By using this advanced imaging, doctors hope to improve diagnosis and treatment planning for patients.

To participate in this trial, candidates must be adults aged 18 and older who have suspected or diagnosed cancer, and they should be scheduled for a PSMA PET/CT scan. It's important that participants can give their consent to join the study. However, individuals with non-cancerous conditions, those who are pregnant, or those who cannot provide consent are not eligible. If you decide to join, you can expect to undergo the PSMA PET/CT scan as part of the study, and your experience will contribute to understanding how this imaging can help in managing prostate cancer better.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • - (i) adult patients (aged 18 years or order); (ii) patients with suspected or new diagnosed or previously treated malignant tumors (supporting evidence may include MRI, CT, tumor markers and pathology report); (iii) patients who had scheduled PSMA PET/CT scan; (iv) patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.
• Exclusion Criteria:
• • - (i) patients with non-malignant lesions; (ii) patients with pregnancy; (iii) the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.